# To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus

> **NCT03495765** · PHASE3 · COMPLETED · sponsor: **Marsden Eye Specialists** · enrollment: 160 (actual)

## Conditions studied

- Diabetic Macular Oedema

## Interventions

- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT03495765
- **Lead sponsor:** Marsden Eye Specialists
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2017-01-01
- **Final completion:** 2017-01-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2018-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03495765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03495765, "To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03495765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*